These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 7997176)

  • 1. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
    Yamagishi J; Kojima T; Oyamada Y; Fujimoto K; Hattori H; Nakamura S; Inoue M
    Antimicrob Agents Chemother; 1996 May; 40(5):1157-63. PubMed ID: 8723458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
    Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
    J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
    Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H; Wiedemann B; Heisig P
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Ito H; Yoshida H; Bogaki-Shonai M; Niga T; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2014-23. PubMed ID: 7811012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
    Ferrero L; Cameron B; Crouzet J
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
    Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
    Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.